<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04055636</url>
  </required_header>
  <id_info>
    <org_study_id>PR_01</org_study_id>
    <nct_id>NCT04055636</nct_id>
  </id_info>
  <brief_title>Observational Trial of Cardiotoxicity in Patients Undergoing Chemotherapy.</brief_title>
  <acronym>PROMETEY</acronym>
  <official_title>Prospective Multidisciplinary Observational Trial of Cardiotoxicity in Patients Undergoing Anticancer Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moscow State University of Medicine and Dentistry</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Moscow State University of Medicine and Dentistry</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Advances in treatment have led to improved survival of patients with cancer, but have also
      increased morbidity and mortality due to cancer treatment side effects. Cardiotoxicity is one
      the most frequent side effect which may lead to premature morbidity and death among cancer
      survivors. The most concerning cardiovascular complications of cancer therapy is myocardial
      dysfunction, leading to heart failure, and fatal arrhythmias, especially those induced by
      QT-prolonging drugs.

      PROMETEY (PROspective Multidisciplinary obsErvational Trial of cardiotoxicity in patiEnts
      undergoing anticancer therapy) - is Russian multicenter observational study assessing
      cardiotoxicity and its clinical, biochemical and genetic factors in patients on cancer
      therapy.

      The objectives of the study are:

        -  to reveal prevalence of cardiotoxic effects of cancer therapy in routine clinical
           practice in Russian Federation,

        -  to assess contribution of these effects to mortality of patients on cancer therapy,

        -  to evaluate clinical and economic consequences of cardiotoxicity in patients with
           cancer,

        -  to develop an individualized model of cardiotoxicity risk factors based on clinical and
           laboratory parameters.

      Patients: 400 cancer patients with toxic cardiomyopathy and 100 patients with idiopathic or
      family dilated cardiomyopathy.

      Study duration: 60 months. All patients will undergo complex examination after signing
      informed consent form(ICF): physical exam, echocardiography with speckle tracking analysis,
      ambulatory 48-hours ECG monitoring, biochemistry, analysis of biomarkers of myocardial
      injury, fibrosis and inflammation.

      Primary endpoint: all-cause mortality, heart transplantation, cardioverter-defibrillator
      implantation, hospitalization with heart failure decompensation.

      Secondary endpoints:

        -  thromboembolism,

        -  fatal/ nonfatal myocardial infarction, stroke,

        -  sudden cardiac death,

        -  surgical therapy of heart failure or arrhythmias,

        -  cardiovascular death,

        -  all-cause mortality,

        -  heart transplantation,

        -  cardioverter-defibrillator implantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2019</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>During all observational period (60 months)</time_frame>
    <description>Death of patient from all causes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart transplantation</measure>
    <time_frame>During all observational period (60 months).</time_frame>
    <description>Heart transplantation associated with heart failure or toxic cardiomyopathy decompensation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardioverter-defibrillator implantation</measure>
    <time_frame>During all observational period (60 months).</time_frame>
    <description>Implantation of cardioverter-defibrillator associated with life-threatening ventricular arrhythmias.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospitalization with heart failure decompensation</measure>
    <time_frame>During all observational period (60 months)</time_frame>
    <description>Hospitalization of patient due to decompensation of heart failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thromboembolism.</measure>
    <time_frame>During all observational period (60 months).</time_frame>
    <description>Venous thromboembolism associated with cancer disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>During all observational period (60 months).</time_frame>
    <description>Fatal/nonfatal myocardial infarction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>During all observational period (60 months).</time_frame>
    <description>Stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sudden cardiac death</measure>
    <time_frame>During all observational period (60 months).</time_frame>
    <description>Sudden cardiac death associated with fatal arrhythmias.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical therapy of heart failure or arrhythmias</measure>
    <time_frame>During all observational period (60 months).</time_frame>
    <description>Surgical therapy of heart failure or arrhythmias.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>During all observational period (60 months).</time_frame>
    <description>Death of patient associated with cardiovascular disease.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cardiotoxicity</condition>
  <condition>Heart Failure</condition>
  <condition>Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>cancer survivors with heart failure and/or fatal arrhythmias</arm_group_label>
    <description>Patients undergoing cancer therapy for the last 3-4 years with signs of heart failure and/or life-threatening arrhythmias. Administered interventions: physical examination, echocardiography with speckle tracking analysis, 48-hour ECG monitoring, blood samples analysis for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cancer survivors without complications</arm_group_label>
    <description>Patients undergoing cancer therapy for the last 3-4 years without signs of heart failure and/or life-threatening arrhythmias. Administered interventions: physical examination, echocardiography with speckle tracking analysis, 48-hour ECG monitoring, blood samples analysis for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cancer patients before chemotherapy</arm_group_label>
    <description>Cancer patients before administered chemotherapy. Interventions: physical examination, echocardiography with speckle tracking analysis, 48-hour ECG monitoring, blood samples analysis for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with non-toxic dilated cardiomyopathy (control).</arm_group_label>
    <description>Patients with non-toxic dilated cardiomyopathy. Administered interventions: physical examination, echocardiography with speckle tracking analysis, 48-hour ECG monitoring, blood samples analysis for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Echocardiography with speckle tracking analysis.</intervention_name>
    <description>Transthoracic echocardiography with speckle tracking analysis.</description>
    <arm_group_label>Cancer patients before chemotherapy</arm_group_label>
    <arm_group_label>Cancer survivors without complications</arm_group_label>
    <arm_group_label>Patients with non-toxic dilated cardiomyopathy (control).</arm_group_label>
    <arm_group_label>cancer survivors with heart failure and/or fatal arrhythmias</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>48-hour ECG monitoring.</intervention_name>
    <description>Ambulatory 48-hour electrocardiography monitoring.</description>
    <arm_group_label>Cancer patients before chemotherapy</arm_group_label>
    <arm_group_label>Cancer survivors without complications</arm_group_label>
    <arm_group_label>Patients with non-toxic dilated cardiomyopathy (control).</arm_group_label>
    <arm_group_label>cancer survivors with heart failure and/or fatal arrhythmias</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood samples analysis.</intervention_name>
    <description>Analysis of blood samples for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.</description>
    <arm_group_label>Cancer patients before chemotherapy</arm_group_label>
    <arm_group_label>Cancer survivors without complications</arm_group_label>
    <arm_group_label>Patients with non-toxic dilated cardiomyopathy (control).</arm_group_label>
    <arm_group_label>cancer survivors with heart failure and/or fatal arrhythmias</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, plasma.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female more than 18 years old with verified cancer or with non-toxic dilated
        cardiomyopathy (control group).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent form (ICF),

          -  Eastern Cooperative Oncology Group (ECOG) scale 0-3,

          -  patients with verified cancer on or planned to be on chemotherapy including
             anthracyclines,

          -  sufficient bone marrow function, including: absolute neutrophils &gt; 1.5*10^9/l,
             platelets &gt; 100*10^9/l, hemoglobin &gt; 9 g/dl,

          -  sufficient liver function, including: total bilirubin &lt; 1.5*upper normal value,
             aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 2.5 upper normal
             value,

          -  sufficient renal function, including: creatinine clearance &gt; 50 ml/min.

        For control group:

          -  verified non-toxic dilated cardiomyopathy.

        Exclusion Criteria:

          -  refusal of patient,

          -  sepsis,

          -  coma, delirium,

          -  mental disorders,

          -  left chest radiation therapy,

          -  metastases in central nervous system.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yury A Vasyuk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moscow State University of Medicine and Dentistry</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elena Y Shupenina, PhD</last_name>
    <phone>+79161906122</phone>
    <email>eshupenina@mail.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moscow State University of Medicine and Dentistry, Department of Hospital Therapy â„–1</name>
      <address>
        <city>Moscow</city>
        <state>Moscow Region</state>
        <zip>107095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Shupenina, PhD</last_name>
      <phone>+79161906122</phone>
      <email>eshupenina@mail.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>August 14, 2019</last_update_submitted>
  <last_update_submitted_qc>August 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

